Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHACE 1: DCV/ASV/Beclabuvir ± RBV in HCV Genotype 1a
NCT02098616Phase 2Completed
- Start
- Jul 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C (HCV) (6 arms). Primary endpoint: Sustained Virologic Response at Post-Treatment Week 12. Started Jul 2014; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02098616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098616.